Welcome back to Plenary Session and the Drug Development Letter.

I'm joined by my friend and colleague, Dr. Timothy Olivier from Geneva, Switzerland.

It's good to see you, Timothy. It's good to see.

Hi, I, how are you doing?

I'm doing well.

I was recently in ASCO, and I was giving a couple of lectures, and throughout the lectures, people came up to me afterward, and they said,

where's Timothy? We need Timothy here. So back by popular demand. Here you are.

I would have been glad to join. Actually, I was in Chicago in the mountains in Switzerland.

So this was also interesting, but I would have enjoyed to be there with you and everybody.

The closest thing, the closest things.

Chicago in the mountains.

All right, we're here with the special Post-Asco edition.

Let's go to the next slide.

And we're going to talk about several of the abstracts and presentations

that we thought were most interesting.

Laura, we cover this in the pregame session.

We're going to revisit it now. Crown,

which was an interesting, the first time you've ever seen anything like it. That's what some

people say. Nadina, Checkmate 9DW, Transmet and Post Monarch. So let's get started. Let's get

into Laura. Laura's, of course, the randomized control trial of stage

3B, non-small cell lung cancer, people with EGFR mutation positive, who are getting osmertinib

versus placebo after concurrent or sequential chemo r.T. So, Timothy, what do you think? What did we

...